Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lawsuit against Impax generic drug dismissed
<p>Concerta is marketed by McNeil Consumer & Speciality Pharmaceuticals, a division of Johnson & Johnson, as a once-daily treatment for attention deficit disorder.<br /><br />Alza Corporation and McNeil
<p>Concerta is marketed by McNeil Consumer & Speciality Pharmaceuticals, a division of Johnson & Johnson, as a once-daily treatment for attention deficit disorder.<br /><br />Alza Corporation and McNeil
Positive phase III data demonstrated that Humira was statistically superior to methotrexate in patients with psoriasis. Patients with moderate to severe psoriasis receiving Abbott’s Humira achieved at least
This response was seen in over 90% of patients. These rates have never been attained in clinical trials of HIV patients living with drug-resistant virus. Fuzeon is co-developed
The study, which will commence next month, will evaluate the safety and tolerability of PBT2. In addition, it will examine the drug’s mechanism of action and indicators of
The move follows Reckitt Benckiser’s global acquisition of Alliance Boots’ over-the-counter healthcare business, with The Boots Company being a subsidiary of Alliance Boots. Instead of paying the Boots
Significant improvements were also noted in the amount of assistance required by caregivers. A reduction was noted in both hours of care provided each week as well as
The second phase of this exploratory trial was designed to assess the safety, tolerability, pharmacokinetics, and response to treatment with AVI’s proprietary compound, AVI-4065, developed from the company’s
The candidate H5N1 pandemic vaccine was produced using the company’s proprietary vero cell-based technology and is the first clinical evaluation of a vaccine using cell based technology. Preliminary
LAB CGRP, as a potential drug, has demonstrated in preclinical studies a profile that could make it an ideal anti-asthmatic drug candidate. LAB CGRP showed statistically significant broncho-protective
Oral fludarabine is currently marketed by Schering AG in the EU and Canada under the trade name, Fludara, for the treatment of relapsed B-cell chronic lymphocytic leukemia (CLL).